Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 3/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196382 | 0.94 | MEN1 (0.38) | SIRT6SIRT1SMN1; SMN2GLP1RSIRT5 | |
| SCHEMBL12706048 | 0.84 | MEN1 (0.38) | SIRT6SIRT1GLP1RTLR2MEN1 | |
| SCHEMBL13839054 | 0.83 | TLR2 (0.40) | SIRT6SIRT1GLP1RTLR2FOLH1 | |
| SCHEMBL13749785 | 0.79 | SIRT6 (0.48) | SIRT6SIRT1SMN1; SMN2GLP1RSIRT5 | |
| SCHEMBL22225476 | 0.78 | SIRT6 (0.52) | SIRT6SIRT1GLP1RSIRT5TLR2 | |
| SCHEMBL15256905 | 0.78 | SIRT6 (0.58) | SIRT6SIRT1GLP1RSIRT5TLR2 | |
| SCHEMBL14960655 | 0.78 | SIRT6 (0.49) | SIRT6SIRT1GLP1RSIRT5TLR2 | |
| SCHEMBL15256893 | 0.76 | SIRT6 (0.42) | SIRT6SIRT1SMN1; SMN2GLP1RSIRT5 | |
| SCHEMBL13635152 | 0.76 | SIRT6 (0.59) | SIRT6SIRT1GLP1RSIRT5TLR2 | |
| SCHEMBL14942519 | 0.75 | SIRT6 (0.47) | SIRT6SIRT1SMN1; SMN2GLP1RSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528104-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | EPOR, PROKR1, EDNRB | SIRT6 3745/4885SIRT1 4168/4885SMN1; SMN2 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.